BioCentury

7:00 AM GMT, Sep 16, 2002
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Avastin: Quick hit didn’t pay off

Genentech Inc. took a gamble with its Avastin anti-VEGF antibody in metastatic breast cancer and it failed to pay off last week, as the compound failed to show progression-free survival in a Phase III trial. But by taking on a population with more advanced disease and

Read the full 464 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.